Esomeprazole Magnesium

Treats heartburn and other symptoms associated GERD. ANDA 217022, held by Zhejiang Yongtai. Esomeprazole Magnesium.

As of Nov 15, 2026, ANDA 217022 (Esomeprazole Magnesium), held by Zhejiang Yongtai, was first approved by FDA on Dec 27, 2023, with 0 approved supplements and 0 published complete response letters.

First approved: Dec 27, 2023
Review: Standard
Supplements approved: 0
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

Esomeprazole magnesium is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the:

Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age.
Maintenance of healing of EE in adults.
Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age.
Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first

Date	Submission	Status	Documents
Dec 27, 2023	Original application	Approved	None posted

Products

2 strengths and forms


Esomeprazole MagnesiumEQ 20MG BASE · capsule, delayed rel pellets;oral	Esomeprazole Magnesium	Rx
Esomeprazole MagnesiumEQ 40MG BASE · capsule, delayed rel pellets;oral	Esomeprazole Magnesium	Rx

Identifiers

Application: ANDA 217022
Drugs@FDA: Overview at FDA
Company: Zhejiang Yongtai

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters